<DOC>
	<DOCNO>NCT02307240</DOCNO>
	<brief_summary>This Phase I , open-label , multi-center trial design evaluate safety , tolerability pharmacokinetics CUDC-907 administer orally subject advanced/relapsed solid tumor .</brief_summary>
	<brief_title>Open Label , Multi-center Study Assess Safety , Tolerability Pharmacokinetics CUDC-907 Subjects With Advanced/Relapsed Solid Tumors</brief_title>
	<detailed_description>This Phase I , open-label , multi-center trial design evaluate safety , tolerability pharmacokinetics CUDC-907 administer orally subject advanced/relapsed solid tumor . The follow dosing schedule may examine , consist 21-day treatment cycle : 1 . Three day weekly Days 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 ( TIW schedule ) . 2 . Five day on/two day Days 1 5 , 8 12 , 15 19 ( 5/2 schedule ) . 3 . Four day on/three day Days 1 4 , 8 11 , 15 18 ( 4/3 schedule ) .</detailed_description>
	<criteria>1 . Subjects â‰¥18 year age 2 . Histopathologically confirm diagnosis advance solid tumor breast cancer midline carcinoma NUT rearrangement , progress despite standard therapy , standard therapy exists . In case breast cancer , must ER+ PR+ , Her2 negative disease ( woman ) disease progression least one prior hormonal therapy advanced/metastatic disease disease relapse adjuvant hormonal therapy 3 . Measurable evaluable disease 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 5 . Recovery Grade 1 baseline toxicity due prior systemic treatment radiotherapy ( exclude alopecia ) . Note : subject HR+/Her2 negative breast cancer : ongoing treatment follow : tamoxifen , anastrozole , exemestane letrozole allow 6 . Adequate hematologic organ function evidence follow laboratory study within two week ( 14 day ) study enrollment : Absolute neutrophil count 1,500/L ; platelet 100,000/L ; hemoglobin &gt; 9 g/dL ; creatinine 1.5x upper limit normal ( ULN ) ; total bilirubin ( Tbili ) 1.5x ULN ; aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) 2.5x ULN ; serum albumin &gt; 3 g/dl ; partial thromboplastin time INR &lt; 1.2 x ULN ( unless receive therapeutic anticoagulation ) 7 . For subject diabetes , adequate blood sugar control evidence hemoglobin A1c value &lt; 8 % 8 . Women childbearing potential must negative serum urine pregnancy test 9 . Men woman childbearing potential must agree use adequate birth control throughout participation study 30 day follow last study treatment 10 . Able provide write informed consent follow protocol requirement 1 . Systemic anticancer therapy within three week study entry , except nitrosoureas mitomycin C within six week 2 . Radiotherapy within one week prior start study treatment 3 . Other investigational agent ( ) within 21 day prior start study treatment 4 . Symptomatic central nervous system ( CNS ) involvement lymphangitic metastasis . Stable improve CNS disease active treatment receipt adequate therapy allow 5 . Uncontrolled severe cardiovascular disease , include myocardial infarction unstable angina within six month prior study treatment , New York Heart Association ( NYHA ) Class II great congestive heart failure , serious arrhythmia require medication treatment , clinically significant pericardial disease cardiac amyloidosis 6 . Diabetes mellitus uncontrolled medication 7 . Ongoing diarrhoea define one watery stool/day 8 . Serious infection require systemic antibiotic therapy within 14 day prior study treatment 9 . Immunosuppressive medication within 7 day prior first dose CUDC907 . Inhaled topical corticosteroid permit , replacement dose steroid ( define &lt; 30 mg/day hydrocortisone equivalent ) provide subject stable taper dose least 14 day prior first dose CUDC907 10 . Second primary malignancy within two year study entry require active treatment 11 . Known gastrointestinal condition would interfere swallow oral absorption/tolerance CUDC907 12 . Known positive status human immunodeficiency virus ( HIV ) hepatitis B surface antigen , know suspect hepatitis C infection 13 . Pregnancy ongoing breastfeed status 14 . Unstable clinically significant concurrent condition ( e.g . medical psychological ) would , opinion investigator , jeopardize subject safety and/or compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>NMC</keyword>
</DOC>